Schedule of events – bio
J. New innovations in construction technology Joseph Kim, PhD, entrepreneur, immunologist, and health policy leader, is co-founder and chief executive officer of Inovio, a biotechnology company leading the world in developing novel immunotherapies—medicines that attack a broad array of cancers and challenging infectious diseases by training the body’s immune system to identify and fight disease. New innovation technologies dubai He previously developed vaccines for Merck & Co. New innovations partners An immunologist by training, Joseph holds an MIT undergraduate degree, a PhD in biochemical engineering from the University of Pennsylvania, and an MBA from The Wharton School. New innovations for 2014 He has published more than 100 scientific papers, holds numerous patents, and sits on editorial boards and scientific review panels. New innovations in electrical technology In 2015, Dr. New innovations sign in Kim was named Entrepreneur of the Year for Life Sciences by Ernst and Young in the Philadelphia region.
Partners new innovations He also serves on the board of the International Vaccine Institute and the Council of Korean Americans. Vanderbilt new innovations The World Economic Forum selected Dr. New innovations in computer technology 2013 Kim as a member of its Global Agenda Council and named him a Technology Pioneer as well as one of its Young Global Leaders. Www new innovations He is a frequent guest on CNBC’s Fast Money and other financial programs, where he comments on Inovio’s breakthroughs and the pharmaceutical landscape. New technological innovations MIT’s Technology Review magazine called him “one of the world’s top innovators.” Joseph is a Fellow of the inaugural class of the Health Innovators Fellowship and a member of the Aspen Global Leadership Network where he is working with a team to develop a vision of tomorrow’s healthcare system. New innovations in technology in 2015 Jeffrey D. New technology innovations in business Marrazzo, Co-Founder and Chief Executive Officer, Spark Therapeutics
Jeff Marrazzo has led the creation and growth of Spark Therapeutics from a research center within the Children’s Hospital of Philadelphia to a fully integrated gene therapy company that is challenging the inevitability of genetic disease by discovering, developing and delivering potential treatments in ways unimaginable – until now. New innovations log in He also serves on Spark’s board of directors. New technologies trends innovations and research Under Jeff’s leadership, Spark has successfully completed the first randomized, controlled Phase 3 trial of an investigative gene therapy for a genetic disease and established human proof-of-concept of Spark’s gene therapy platform in both the retina and the liver. New innovations ttuhsc The company is currently preparing the first Biologics License Application submission for a gene therapy for a genetic disease in the U.S. New innovations in technology 2016 In the three years since founding Spark, Jeff has raised more than $500 million in capital, established a global collaboration with Pfizer, and built an organization of nearly 200 colleagues. New innovations in computer technology 2014 During a career that has spanned the public and private sectors, Jeff has consistently championed the potential benefits of precision medicine and healthcare reform for patients. New innovations in software technology Prior to Spark, he helped build and sell the first genetic testing benefit management and pharmacogenomics medicines company to CVS Caremark. List of new innovations Previously, Jeff served as an advisor to former Pennsylvania Governor Edward G. New innovations login Rendell, where he led reforms in the financing and delivery of healthcare. New and innovative ideas for business Jeff received a B.A. New inventions and innovations in economics and B.S.E. New innovations in computer technology 2015 in systems science and engineering from the University of Pennsylvania. New innovations in educational technology He also holds a dual M.B.A. New innovations in healthcare technology / M.P.A. New innovations residency from The Wharton School of the University of Pennsylvania and Harvard University, a program which he founded. New innovations in mobile technology Lynn Seely, MD, Chief Executive Officer, Myovant Sciences
Dr. New innovations in banking technology Seely is an endocrinologist with over 20 years of drug development experience and biopharmaceutical company leadership. New innovations residency login At Medivation, she served as Chief Medical Officer from 2005-2015 and led the development of XTANDI® (enzalutamide) for the treatment of metastatic castration-resistant prostate cancer from IND-enabling studies through to NDA approval and post-approval clinical studies. New innovations 2014 Dr. New innovations resident login Seely currently serves on the Board of Directors of Blueprint Medicines Corporation. What is new innovations She completed her residency in internal medicine at Yale-New Haven Hospital and a basic science and clinical fellowship in endocrinology and metabolism at the University of California, San Diego.
New discoveries are finding links that extend significantly beyond the gut microbiome and intestinal disorders into a range of bodily systems including the immune and nervous systems. New innovations and inventions Major biopharma companies have engaged in significant deals that envision treatments to commercialize from this research and leading companies are pushing forward on clinical trials. Best new innovations This session will outline the microbiome influenced therapies most likely to create major effects for patients.
The maturation of new cancer treatment technologies has produced a mix of highly positive patient outcomes and some serious clinical holds, while investments for manufacturing and commercialization continue to accelerate. New innovations in packaging technology This session will dive into the assumptions underlying the most aggressive approaches and the ways of reducing the risks of failure along the way to delivering immuno-oncology’s promise to patients broadly.
The passage by Congress of the 21 st Century Cures Act in late 2016 has opened up new opportunities and expectations for the design of clinical trials that the FDA will consider for regulatory review. New innovations in medical technology Real world evidence and the stronger inclusion of patient perspectives on endpoints are two examples of the shifts that will impact therapy development. New innovations of 2014 This session will explain the advantages and complications that drug developers and investors should be aware of as the Cures Act gets implemented.
The scourge of rising addiction and heroin overdoses has been associated with the growth in usage of important, opioid-based, prescription pain treatments. New innovations vcu New approaches to pain control are looking at different biological mechanisms and methodologies for improving patients’ lives with lower risks of ill effects or addiction. Rms new innovations This session will speak with experts developing therapeutic innovations that do not rely on opioid-based drugs and can provide doctors additional alternatives for helping patients.
From a healthcare policy point of view, 2017 has the potential of being the most dramatic since the initial introduction of the Affordable Care Act. Lsuhsc new innovations The new Trump Administration has suggested an interest in making wholesale changes in how medicines are regulated and paid for by the U.S. New innovations lsuhsc government. New ideas and religions PDUFA will expire later this year if its planned replacement is not passed in a timely fashion, greatly complicating companies’ drug development strategies and budgets. New ideas and products This session will share the latest details on what policies the Trump Administration and Congress are pursuing that would support or upend the assumptions that biopharma executives and investors have built into their financial models.
• Alex M. New technological innovations 2012 Azar II, Chairman, Seraphim Strategies, LLC; former President, Lilly USA, LLC (2012-2017); former Deputy Secretary, U.S. New innovations lsuhsc login Department of Health and Human Services (2005-2007)
Both innovator companies and payers of medicines have expressed a willingness to look beyond the “fee per pill” model to attributing value to the effects on patients’ health instead. New innovations in 2014 The challenge of reimbursing for curative therapies versus lifelong treatments of chronic conditions presents a special challenge, but one that may shine a light on value-based approaches generally. New technological innovations 2013 This session will explore with the innovators making progress on gene therapies how they are envisioning the reimbursement model in ways that all stakeholders might appreciate, including doctors’, patients’, and payers’ perspectives.
The biopharma industry has seen enormous growth in recent years of the number of start-ups and IPOs, with hundreds of new executive team and board member positions being filled. Www new innovations com login However, the inclusion of underrepresented groups in these influential positions has failed to keep pace with the growth of biopharma companies and too often the decision-makers fail to reflect the employee bases they lead or patient populations they serve. New trends and innovations in information technology This session will focus on practical approaches and successful examples to improve the diversity of leadership recruitment efforts and better align organizations with the full measure of talented people available.
Moderator: Julie L. New technological innovation not yet commercialized Gerberding, MD, MPH, Executive Vice President & Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health, Merck
As biotech IPO activity has cooled from its 2015 peak, companies are more deliberately weighing reverse mergers and other alternatives to benefiting from the capital in public markets. New chairs innovations in design technology and materials With post-election market uncertainty, does the IPO market for 2017 seek to rise, fall, or stay level? What markers should CEOs watch for to gauge their timing and choices? This session will feature experienced voices for explaining the practical techniques for getting into public markets and what investors are expecting to see in order to win their support.
As biosimilar medicine options begin to roll-out in the United States, the regulatory and legal uncertainties are also starting to shrink below the market adoption uncertainties. New technological innovations 2014 As some innovator companies also pursue biosimilar development, and others seek to compete, there are opportunities to learn from jurisdictions that have allowed biosimilar medicines for longer periods, such as Japan and Europe regarding the reactions of doctors and payers. New innovations around the world This session will feature executives from innovator companies explaining how they evaluate biosimilars within their pipelines, plus those with expertise on understanding the economic effects seen when biosimilars launch within a market.
While the past year has seen a fading in the IPO market, the volume of deal flow and valuations for M&A remain high. New innovations in solar technology Many of the largest industry members have strong cash positions, and most analysts continue to expect pipeline enhancement via acquisition. New innovations in information technology 2015 As political forecasts suggest high potential for tax reform and other changes in how international deals might be reviewed, there are multiple ways 2017 could be a great year or a terrible year for biopharma M&A. Cool new innovations This session will talk through the likely and extreme scenarios, as well as provide insight on what signs to watch for from Washington and Wall St. New innovations in information technology along the way.